Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1 Introduction Relapsed or refractory (R/R) B-cell lymphoma remains a major therapeutic challenge, with limited curative options and poor long-term outcomes despite recent advances [1, 2]. The introduction of CD20 × CD3 bispecific antibodies (BsAbs), such as glofitamab and epcoritamab, has transformed the treatment landscape by redirecting endogenous T cells to lyse malignant B cells [3-5].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
